Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Atreca 7.8M share Spot Secondary priced at $16.00 » 06:20
07/16/20
07/16
06:20
07/16/20
06:20
BCEL

Atreca

$18.44 /

+0.24 (+1.32%)

The deal range was…

The deal range was $16.00-$17.00. Cowen, Evercore ISI and Stifel acted as joint book running managers for the offering.

ShowHide Related Items >><<
BCEL Atreca
$18.44 /

+0.24 (+1.32%)

BCEL Atreca
$18.44 /

+0.24 (+1.32%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
BCEL Atreca
$18.44 /

+0.24 (+1.32%)

  • 16
    Jul
BCEL Atreca
$18.44 /

+0.24 (+1.32%)

On The Fly
Fly Intel: After-Hours Movers » 19:05
07/15/20
07/15
19:05
07/15/20
19:05
AA

Alcoa

$12.68 /

+0.07 (+0.56%)

, PIXY

ShiftPixy

$4.72 /

+0.08 (+1.72%)

, HIG

Hartford Financial

$40.41 /

+1.68 (+4.34%)

, NBRV

Nabriva Therapeutics

$0.66 /

+0.0338 (+5.36%)

, RTIX

RTI Surgical

$3.80 /

+0.41 (+12.11%)

, DELL

Dell Technologies

$52.64 /

+0.2 (+0.38%)

, VMW

VMware

$139.57 /

+1.47 (+1.06%)

, SPCE

Virgin Galactic

$18.55 /

+0.105 (+0.57%)

, MNK

Mallinckrodt

$3.10 /

+0.365 (+13.37%)

, DKNG

DraftKings

$32.55 /

+2.31 (+7.64%)

, SNBR

Sleep Number

$53.63 /

+1.84 (+3.55%)

, TCDA

Tricida

$26.20 /

+0.42 (+1.63%)

, APTO

Aptose Biosciences

$6.26 /

+0.61 (+10.80%)

, CYTK

Cytokinetics

$28.98 /

+1.1 (+3.95%)

, BCEL

Atreca

$18.44 /

+0.24 (+1.32%)

, TWTR

Twitter

$35.68 /

+1.28 (+3.72%)

, FEYE

FireEye

$12.36 /

+0.53 (+4.48%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

TCDA Tricida
$26.20 /

+0.42 (+1.63%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

RTIX RTI Surgical
$3.80 /

+0.41 (+12.11%)

PIXY ShiftPixy
$4.72 /

+0.08 (+1.72%)

NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

CYTK Cytokinetics
$28.98 /

+1.1 (+3.95%)

BCEL Atreca
$18.44 /

+0.24 (+1.32%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

06/16/20
Fly Intel: Top five analyst downgrades
06/16/20 Deutsche Bank
Alcoa downgraded to Hold with $10 price target at Deutsche Bank
06/15/20 Deutsche Bank
Alcoa downgraded to Hold from Buy at Deutsche Bank
04/23/20 JPMorgan
Alcoa price target lowered to $12 from $14 at JPMorgan
PIXY ShiftPixy
$4.72 /

+0.08 (+1.72%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

05/05/20 Deutsche Bank
Hartford Financial price target lowered to $53 from $63 at Deutsche Bank
04/14/20 Morgan Stanley
Hartford Financial upgraded to Overweight from Equal Weight at Morgan Stanley
04/08/20 RBC Capital
Hartford Financial price target lowered to $39 from $66 at RBC Capital
04/01/20 Wells Fargo
Hartford Financial upgraded to Overweight from Equal Weight at Wells Fargo
NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
RTIX RTI Surgical
$3.80 /

+0.41 (+12.11%)

06/16/20 Cantor Fitzgerald
RTI Surgical assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
RTI Surgical assumed with an Overweight at Cantor Fitzgerald
01/17/20 Cantor Fitzgerald
RTI Surgical price target raised to $6 from $4 at Cantor Fitzgerald
09/16/19 Sidoti
RTI Surgical initiated with a Buy at Sidoti
DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

07/09/20
Fly Intel: Top five analyst initiations
07/09/20 Daiwa
Dell Technologies initiated with a Neutral at Daiwa
07/07/20 Deutsche Bank
Dell offers 20%-30% upside on standalone basis, says Deutsche Bank
06/30/20 Cowen
Dell Technologies initiated with a Market Perform at Cowen
VMW VMware
$139.57 /

+1.47 (+1.06%)

06/24/20 Bernstein
Potential spinoff would be largely positive for VMware, says Bernstein
06/24/20
Fly Intel: Top five analyst upgrades
06/24/20 Wells Fargo
Dell Technologies price target raised to $70 from $57 at Wells Fargo
SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

07/13/20 Alembic Global
Virgin Galactic initiated with an Overweight at Alembic Global
03/24/20 Morgan Stanley
Morgan Stanley upgrades Virgin Galactic to Overweight after over 70% drop
03/24/20 Morgan Stanley
Virgin Galactic upgraded to Overweight from Equal Weight at Morgan Stanley
03/03/20 Morgan Stanley
Lead up to next lunar landings can have 'powerful impact,' says Morgan Stanley
MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
06/17/20 Citi
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

07/15/20 Rosenblatt
DraftKings recent pullback a buying opportunity, says Rosenblatt
07/14/20 Craig-Hallum
NJ sports betting up despite no sports, iGaming also strong, says Craig-Hallum
07/14/20 Stephens
Stephens more confident in DraftKings position after NJ iGaming data
07/08/20 Jefferies
GVC has 'credible' U.S. sports betting aspirations, says Jefferies
SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

07/10/20
Fly Intel: Top five analyst upgrades
07/10/20 Piper Sandler
Piper Sandler upgrades Sleep Number on 'robust' mattress demand
07/09/20 Piper Sandler
Sleep Number upgraded to Overweight from Neutral at Piper Sandler
03/25/20 Raymond James
Sleep Number downgraded to Market Perform on weak traffic at Raymond James
TCDA Tricida
$26.20 /

+0.42 (+1.63%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

06/12/20 Piper Sandler
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler
06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
CYTK Cytokinetics
$28.98 /

+1.1 (+3.95%)

07/15/20 Cantor Fitzgerald
Cytokinetics price target raised to $41 from $29 at Cantor Fitzgerald
07/15/20 JMP Securities
Cytokinetics price target raised to $29 from $23 at JMP Securities
07/14/20 H.C. Wainwright
Cytokinetics price target raised to $38 from $35 at H.C. Wainwright
07/14/20 Piper Sandler
Cytokinetics price target raised to $33 from $28 at Piper Sandler
BCEL Atreca
$18.44 /

+0.24 (+1.32%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
TWTR Twitter
$35.68 /

+1.28 (+3.72%)

07/15/20 MKM Partners
MKM Partners raises price targets on social media stocks
07/15/20 JPMorgan
Twitter price target raised to $33 from $29 at JPMorgan
07/14/20 Wedbush
Twitter sequential audience growth could surprise positively, says Wedbush
07/10/20 Morgan Stanley
Morgan Stanley says Twitter subscription would need to be $50/year for breakeven
FEYE FireEye
$12.36 /

+0.53 (+4.48%)

04/13/20 BMO Capital
FireEye price target lowered to $12.50 from $17 at BMO Capital
03/05/20
Fly Intel: Top five analyst upgrades
03/05/20 Goldman Sachs
Goldman upgrades FireEye to Buy, sees 33% upside in the shares
03/05/20 Goldman Sachs
FireEye upgraded to Buy from Neutral at Goldman Sachs
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

TCDA Tricida
$26.20 /

+0.42 (+1.63%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

RTIX RTI Surgical
$3.80 /

+0.41 (+12.11%)

PIXY ShiftPixy
$4.72 /

+0.08 (+1.72%)

NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

CYTK Cytokinetics
$28.98 /

+1.1 (+3.95%)

BCEL Atreca
$18.44 /

+0.24 (+1.32%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

  • 16
    Jul
  • 16
    Jul
  • 17
    Jul
  • 19
    Jun
  • 03
    Jun
  • 20
    May
  • 17
    Dec
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

CYTK Cytokinetics
$28.98 /

+1.1 (+3.95%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

Syndicate
Atreca announces offering of Class A common stock, no amount given » 16:04
07/15/20
07/15
16:04
07/15/20
16:04
BCEL

Atreca

$18.55 /

+0.35 (+1.92%)

Atreca announced that it…

Atreca announced that it intends to offer shares of its Class A common stock in an underwritten public offering. Cowen and Company, Evercore Group, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
BCEL Atreca
$18.55 /

+0.35 (+1.92%)

BCEL Atreca
$18.55 /

+0.35 (+1.92%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
BCEL Atreca
$18.55 /

+0.35 (+1.92%)

Recommendations
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler » 10:49
07/08/20
07/08
10:49
07/08/20
10:49
XNCR

Xencor

$32.72 /

-0.2 (-0.61%)

, BCEL

Atreca

$20.75 /

-0.25 (-1.19%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterated an overweight rating and $46 price target on Xencor (XNCR) after the company an Atreca (BCEL) announced a partnership that leverages each company's platform technology to develop first-in-class CD3 targeting bispecific antibodies. While Xencor is a leader in antibody design and manufacturing, Tenthoff says Atreca offers proprietary discovery technology to enable high-throughput multiplex sequencing of B cells from patient samples to yield novel antibody targets. The analyst continues to expect XmAb18087 data in 2H20.

ShowHide Related Items >><<
XNCR Xencor
$32.72 /

-0.2 (-0.61%)

BCEL Atreca
$20.75 /

-0.25 (-1.19%)

XNCR Xencor
$32.72 /

-0.2 (-0.61%)

06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
BCEL Atreca
$20.75 /

-0.25 (-1.19%)

07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
XNCR Xencor
$32.72 /

-0.2 (-0.61%)

BCEL Atreca
$20.75 /

-0.25 (-1.19%)

XNCR Xencor
$32.72 /

-0.2 (-0.61%)

Hot Stocks
Atreca, Xencor to collaborate on T cell-engaging bispecific antibodies » 08:23
07/08/20
07/08
08:23
07/08/20
08:23
BCEL

Atreca

$21.00 /

-2.3 (-9.87%)

, XNCR

Xencor

$32.92 /

+0.15 (+0.46%)

Atreca (BCEL) and Xencor…

Atreca (BCEL) and Xencor (XNCR) announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell-engaging bispecific antibodies as potential therapeutics in oncology. Bispecific antibodies that direct T cells to tumor cells, by simultaneously binding CD3 on T cells and a target on tumor cells, have the potential to drive tumor cell killing. This collaboration will leverage Xencor's XmAb engineering platform to design and manufacture CD3 bispecific antibodies and Atreca's ability to generate novel antibody-target pairs through its discovery platform, including its Immune Repertoire Capture, or IRC, technology. Under the terms of the agreement, the companies will engage in a three-year discovery program. Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells. Up to two joint programs will be mutually selected for further development and commercialization, with each partner sharing 50% of costs and profits. Each company will lead development, regulatory and commercialization activities for one of the joint programs. In addition, the agreement allows for each partner to pursue up to two programs independently, with a mid-to high-single digit percent royalty payable on net sales. Atreca and Xencor began working together in 2019 under a material transfer agreement to accelerate this new collaboration agreement.

ShowHide Related Items >><<
XNCR Xencor
$32.92 /

+0.15 (+0.46%)

BCEL Atreca
$21.00 /

-2.3 (-9.87%)

BCEL Atreca
$21.00 /

-2.3 (-9.87%)

07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
XNCR Xencor
$32.92 /

+0.15 (+0.46%)

06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
XNCR Xencor
$32.92 /

+0.15 (+0.46%)

BCEL Atreca
$21.00 /

-2.3 (-9.87%)

XNCR Xencor
$32.92 /

+0.15 (+0.46%)

Hot Stocks
Xencor, Atreca enter collaboration, license agreement » 08:11
07/08/20
07/08
08:11
07/08/20
08:11
XNCR

Xencor

$32.92 /

+0.15 (+0.46%)

, BCEL

Atreca

$21.00 /

-2.3 (-9.87%)

Xencor (XNCR) and Atreca…

Xencor (XNCR) and Atreca (BCEL) announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell engaging bispecific antibodies as potential therapeutics in oncology. The companies said in a release, "Under the terms of the agreement, the companies will engage in a three-year discovery program. Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells. Up to two joint programs will be mutually selected for further development and commercialization, with each partner sharing 50 percent of costs and profits. Each company will lead development, regulatory and commercialization activities for one of the joint programs. In addition, the agreement allows for each partner to pursue up to two programs independently, with a mid- to high-single digit percent royalty payable on net sales. Atreca and Xencor began working together in 2019 under a material transfer agreement to accelerate this new collaboration agreement."

ShowHide Related Items >><<
XNCR Xencor
$32.92 /

+0.15 (+0.46%)

BCEL Atreca
$21.00 /

-2.3 (-9.87%)

XNCR Xencor
$32.92 /

+0.15 (+0.46%)

06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
BCEL Atreca
$21.00 /

-2.3 (-9.87%)

07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
XNCR Xencor
$32.92 /

+0.15 (+0.46%)

BCEL Atreca
$21.00 /

-2.3 (-9.87%)

XNCR Xencor
$32.92 /

+0.15 (+0.46%)

Over a month ago
Syndicate
Atreca files $300M mixed securities shelf  16:35
07/02/20
07/02
16:35
07/02/20
16:35
BCEL

Atreca

$22.70 /

+0.57 (+2.58%)

 
ShowHide Related Items >><<
BCEL Atreca
$22.70 /

+0.57 (+2.58%)

BCEL Atreca
$22.70 /

+0.57 (+2.58%)

07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
BCEL Atreca
$22.70 /

+0.57 (+2.58%)

Syndicate
Atreca files to sell 9.47M shares of Class A common stock for holders  16:24
07/02/20
07/02
16:24
07/02/20
16:24
BCEL

Atreca

$22.70 /

+0.57 (+2.58%)

 
ShowHide Related Items >><<
BCEL Atreca
$22.70 /

+0.57 (+2.58%)

BCEL Atreca
$22.70 /

+0.57 (+2.58%)

07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
BCEL Atreca
$22.70 /

+0.57 (+2.58%)

Recommendations
Atreca price target raised to $33 from $23 at Canaccord » 07:37
07/01/20
07/01
07:37
07/01/20
07:37
BCEL

Atreca

$21.31 /

+0.8 (+3.90%)

Canaccord analyst John…

Canaccord analyst John Newman raised the firm's price target on Atreca to $33 from $23 and keeps a Buy rating on the shares. The analyst came away from the company's R&D day with increased confidence that its ATRC-101 specifically targeted differentiated PABP-1 present in tumors and he believes the data supports a novel mechanism of action with broad oncology potential.

ShowHide Related Items >><<
BCEL Atreca
$21.31 /

+0.8 (+3.90%)

BCEL Atreca
$21.31 /

+0.8 (+3.90%)

06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
BCEL Atreca
$21.31 /

+0.8 (+3.90%)

Conference/Events
Atreca holds a conference call » 16:25
06/15/20
06/15
16:25
06/15/20
16:25
BCEL

Atreca

$19.08 /

+1.6 (+9.15%)

Management presents…

Management presents pre-clinical data on the Company's lead product candidate, ATRC-101, on a conference call to be held on June 15 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
BCEL Atreca
$19.08 /

+1.6 (+9.15%)

BCEL Atreca
$19.08 /

+1.6 (+9.15%)

06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
BCEL Atreca
$19.08 /

+1.6 (+9.15%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.